| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
21,521 |
18,784 |
$3.07M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
18,951 |
15,769 |
$2.74M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,770 |
8,014 |
$654K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
9,236 |
8,196 |
$642K |
| 71045 |
Radiologic examination, chest; single view |
4,617 |
3,716 |
$577K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,272 |
3,445 |
$534K |
| 71046 |
Radiologic examination, chest; 2 views |
3,241 |
2,764 |
$463K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,274 |
3,992 |
$316K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,410 |
2,944 |
$258K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,502 |
1,344 |
$253K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,456 |
3,731 |
$180K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,383 |
3,379 |
$178K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,244 |
712 |
$140K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
308 |
243 |
$126K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,550 |
2,819 |
$126K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,427 |
4,421 |
$125K |
| 80053 |
Comprehensive metabolic panel |
16,496 |
13,679 |
$114K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
21,414 |
17,833 |
$108K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
682 |
595 |
$64K |
| 36415 |
Collection of venous blood by venipuncture |
19,417 |
15,791 |
$59K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,479 |
2,340 |
$56K |
| 87634 |
|
942 |
812 |
$53K |
| 70450 |
Computed tomography, head or brain; without contrast material |
488 |
382 |
$43K |
| 84484 |
|
5,302 |
3,152 |
$42K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,381 |
359 |
$33K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
261 |
235 |
$32K |
| 59025 |
Fetal non-stress test |
105 |
40 |
$30K |
| 81025 |
|
5,145 |
4,346 |
$28K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
510 |
357 |
$25K |
| A0425 |
Ground mileage, per statute mile |
625 |
436 |
$24K |
| 83735 |
|
4,410 |
3,724 |
$21K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
29 |
26 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,330 |
944 |
$17K |
| 83690 |
|
4,037 |
3,388 |
$17K |
| 81001 |
|
6,176 |
5,124 |
$13K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
419 |
104 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
254 |
227 |
$12K |
| 87631 |
|
117 |
107 |
$11K |
| 80050 |
General health panel |
69 |
67 |
$11K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
441 |
394 |
$9K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,799 |
1,500 |
$8K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
27 |
24 |
$8K |
| 99218 |
|
58 |
15 |
$8K |
| 80061 |
Lipid panel |
810 |
726 |
$8K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
251 |
223 |
$7K |
| 82607 |
|
389 |
336 |
$5K |
| 85730 |
|
1,111 |
919 |
$5K |
| 85610 |
|
1,186 |
984 |
$4K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
191 |
135 |
$3K |
| 76830 |
Ultrasound, transvaginal |
15 |
15 |
$3K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
15 |
15 |
$3K |
| 80076 |
|
543 |
455 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
85 |
80 |
$3K |
| 71250 |
|
20 |
14 |
$3K |
| 82746 |
|
222 |
187 |
$3K |
| 84207 |
|
116 |
108 |
$3K |
| 81003 |
|
1,555 |
1,276 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
99 |
78 |
$3K |
| 82077 |
|
218 |
179 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
208 |
188 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
37 |
14 |
$1K |
| 82728 |
|
102 |
95 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
36 |
29 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
222 |
183 |
$1K |
| 83880 |
|
33 |
25 |
$913.39 |
| 84145 |
|
41 |
38 |
$728.20 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
33 |
12 |
$719.12 |
| 87486 |
|
27 |
24 |
$712.06 |
| 87581 |
|
27 |
24 |
$712.06 |
| 85379 |
|
90 |
83 |
$703.97 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
36 |
28 |
$695.52 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
27 |
24 |
$641.88 |
| 83540 |
|
104 |
95 |
$611.08 |
| 87430 |
|
99 |
87 |
$575.56 |
| 84443 |
Thyroid stimulating hormone (TSH) |
58 |
46 |
$567.02 |
| 84439 |
|
78 |
68 |
$537.59 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
27 |
25 |
$442.21 |
| 87420 |
|
68 |
54 |
$339.42 |
| 84703 |
|
47 |
40 |
$253.81 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
19 |
13 |
$201.88 |
| 87040 |
|
22 |
12 |
$123.84 |
| 81002 |
|
96 |
84 |
$98.12 |
| 85027 |
|
17 |
17 |
$85.66 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,798 |
1,438 |
$39.59 |
| 87081 |
|
25 |
16 |
$24.04 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
20 |
12 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
34 |
25 |
$0.00 |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
14 |
12 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
141 |
116 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
431 |
332 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
139 |
85 |
$0.00 |
| 94726 |
|
13 |
12 |
$0.00 |
| 94729 |
|
13 |
12 |
$0.00 |